Immune system changes after Whipple surgery
Part of Digestive system, Infections clinical trials.
This study is looking at how the immune system can become weakened after a Whipple procedure for pancreatic tumors. The goal is to better understand and potentially help patients recover more effectively.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are scheduled to have a Whipple procedure (pancreaticoduodenectomy) to remove a tumor in the head of your pancreas.
- You are at least 18 years old.
- You do not have an active infection at the time you join the study.
- You are not taking medications that suppress your immune system (like high-dose steroids or biologics) and do not have a condition that weakens your immune system.
- You are not pregnant, breastfeeding, or planning to become pregnant during the study.
- You agree to participate and are able to sign a consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at factors that can predict a serious complication called a pancreatic fistula (a leak from the pancreas) after a Whipple procedure. The goal is to help doctors better understand and manage this risk.
This trial is testing whether draining the main pancreatic and bile ducts during a Whipple procedure can lower the risk of a pancreatic leak. The study focuses on people with a higher chance of this complication.
This study looks at removing certain lymph nodes near the aorta while doing a standard Whipple operation for pancreatic head cancer. The goal is to see whether this approach can improve how well doctors manage the cancer spread.
This trial compares removing the entire pancreas (total pancreatectomy) versus removing only the head (standard Whipple) for certain cancers of the pancreas, bile duct, or ampulla. It is for people whose surgeon thinks the pancreas connection after surgery is likely to leak, which can cause serious complications.
This Phase 3 trial studies a pancreatic surgery approach (pylorus-preserving Whipple or similar) and, in some cases, moving your insulin-making cells into your body to help prevent a dangerous post-surgery leak from the pancreas. It may help people who are considered high risk for this complication based on pancreas texture and duct size.
This trial tests a combination of two immunotherapy drugs (durvalumab and oleclumab) given before surgery to people with pancreatic cancer that can be removed. The goal is to see if this treatment helps the immune system fight the cancer better.
Hear when a new Pancreatic Ductal Adenocarcinoma (mPDAC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.